The Worldwide Microbiome Therapeutics Industry is Projected to Reach $4.7 Billion by 2027 – ResearchAndMarkets.com

The Worldwide Microbiome Therapeutics Industry is Projected to Reach $4.7 Billion by 2027 – ResearchAndMarkets.com




The Worldwide Microbiome Therapeutics Industry is Projected to Reach $4.7 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Microbiome Therapeutics: Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Microbiome Therapeutics estimated at US$199.1 Million in the year 2020, is projected to reach a revised size of US$4.7 Billion by 2027, growing at a CAGR of 57.2% over the analysis period 2020-2027.

C. Difficile Infection, one of the segments analyzed in the report, is projected to record a 53.9% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Obesity segment is readjusted to a revised 57.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $60.7 Million, While China is Forecast to Grow at 54.6% CAGR

The Microbiome Therapeutics market in the U.S. is estimated at US$60.7 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$749.9 Million by the year 2027 trailing a CAGR of 54.6% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 50.7% and 48.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 38.6% CAGR.

Primary Hyperoxyurea Segment to Record 60.2% CAGR

In the global Primary Hyperoxyurea segment, USA, Canada, Japan, China and Europe will drive the 60.2% CAGR estimated for this segment.

These regional markets accounting for a combined market size of US$32.5 Million in the year 2020 will reach a projected size of US$879.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 46 Featured) –

  • 4D pharma plc
  • AOBiome
  • Enterome SA
  • Evelo Biosciences, Inc.
  • Ferring International
  • Immuron Ltd.
  • LNC Therapeutics
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • OxThera AB
  • Rebiotix, Inc.
  • Ritter Pharmaceuticals, Inc.
  • Second Genome
  • Seres Therapeutics, Inc.
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.

What’s New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies – Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Microbiome Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/4mrxo0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900